clinical trials

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Tonix Pharmaceuticals CEO to present commercial CNS portfolio at BIO-Europe Spring 2026, showcasing TONMYA® fibromyalgia launch success with 1,500+ prescriptions since November 2025.

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.

Rosen Law Firm seeks lead plaintiffs in securities class action against Corcept Therapeutics, alleging misrepresentation of FDA communications and clinical trial data for relacorilant drug.

Class action lawsuit filed against Corcept Therapeutics alleges material misstatements about relacorilant drug trials and regulatory approval prospects, covering investors from October 2024 through December 2025.

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.

DelveInsight's 2026 report reveals robust clinical pipeline for pseudomonal infections, with major pharma including AstraZeneca advancing promising therapies addressing antibiotic-resistant pathogens.

MediciNova executives to present clinical pipeline at March 2026 ROTH Conference, conducting direct investor meetings in Dana Point.

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.

Class action lawsuit filed against $CORP alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.

Rosen Law Firm notifies $CORT investors of securities class action alleging misrepresentation of clinical trial data for relacorilant drug and undisclosed FDA concerns.

Ascentage Pharma will report 2025 full-year unaudited results on March 25, 2026, with dual-language investor webcasts highlighting performance of its approved cancer therapies and clinical pipeline progress.

CRISPR Therapeutics stock fell 12% after announcing a $350M convertible debt offering. Analysts remain bullish, suggesting the decline may present a buying opportunity.

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.

SciSparc's NeuroThera Labs acquires 54% of quantum clinical trials company CliniQuantum for $9.46M in stock plus $2.5M earn-out, closing by March 2026.